Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors—a novel antiproliferative/antiangiogenic strategy in thyroid cancer

Author： Hoffmann S. Gläser S. Wunderlich A. Lingelbach S. Dietrich C. Burchert A. Müller H. Rothmund M. Zielke A.

Publisher： Springer Publishing Company

ISSN： 1435-2443

Source： Langenbeck's Archives of Surgery, Vol.391, Iss.6, 2006-11, pp. : 589-596

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines 1

By Farivar R.S. Gardner-Thorpe J. Ito H. Arshad H. Zinner M.J. Ashley S.W. Whang E.E.

Journal of Surgical Research, Vol. 115, Iss. 2, 2003-12 ,pp. : 219-225

Elsevier

Access to resources Recommend Favorite

Protein kinase inhibitors: novel tools in cancer therapy

By Marmé D.

Der Urologe A, Vol. 43, Iss. 3, 2004-09 ,pp. : 148-148

Springer Publishing Company

Access to resources Recommend Favorite

Association Between EGF, TGF-1, VEGF Gene Polymorphism and Colorectal Cancer

By Wu Guo-yang

World Journal of Surgery, Vol. 33, Iss. 1, 2009-01 ,pp. : 124-129

Springer Publishing Company

Access to resources Recommend Favorite

Expression of pro-angiogenic growth hormones VEGF, EGF and BFGF in prostate cancer and their topographic relation to neovascularisation: Hints for a paracrine stimulation?

By Trojan L. Grobholz R. Knoll T. Alken P. Michel M.S.

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 38-38

Elsevier

Access to resources Recommend Favorite

Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer

By Trojan Lutz

Urological Research, Vol. 32, Iss. 2, 2004-05 ,pp. : 97-103

Springer Publishing Company

Access to resources Recommend Favorite